Net income
-294 million USD
2025-07-01 – 2026-06-30
Fundies. English
Apogee Therapeutics, Inc.
EDGAR19 filing records in this dataset, filed from 2023-06-22 to 2026-08-10. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 106 million USD Source
Exact value
105600000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 75.3 million shares Source
Exact value
75339499 shares
Reported share-count change
28.65% · 16.8 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-244 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -164800000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -110506000 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -227500000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -164800000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -55600000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -127000000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -55600000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure
5.15 million USD
2025-01-01 – 2025-12-31
Exact inputs and evidence
- Capital expenditure: 4317000 USD · 2025-01-01 – 2025-03-31 Source
- Capital expenditure: 5085000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 4317000 USD · 2025-01-01 – 2025-03-31 Source
- Capital expenditure: 5085000 USD · 2025-01-01 – 2025-09-30 Source
- Capital expenditure: 5085000 USD · 2025-01-01 – 2025-06-30 Source
- Capital expenditure: 5147000 USD · 2025-01-01 – 2025-12-31 Source
- Capital expenditure: 5085000 USD · 2025-01-01 – 2025-09-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-10.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 3 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2025-12-31
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 73.7 millionPrior period
−USD 182.15 million
–
Current period
−USD 255.84 million
–
Exact inputs and evidence
-255843000 − -182146000 = -73697000 USD
-182146000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-255843000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 56.33 millionPrior period
−USD 171.17 million
–
Current period
−USD 227.5 million
–
Exact inputs and evidence
-227500000 − -171174000 = -56326000 USD
-171174000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-227500000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+346.8%Prior period
USD 1.15 million
–
Current period
USD 5.15 million
–
Exact inputs and evidence
5147000 − 1152000 = 3995000 USD
1152000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source5147000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | −USD 83.99 million Exact valueExact value: -83985000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 74.76 million Exact valueExact value: -74761000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 167,000 Exact valueExact value: 167000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 74.93 million Calculation and evidence-74761000 − 167000 USD Exact free cash flow: -74928000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 182.15 million Exact valueExact value: -182146000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 171.17 million Exact valueExact value: -171174000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 1.15 million Exact valueExact value: 1152000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 172.33 million Calculation and evidence-171174000 − 1152000 USD Exact free cash flow: -172326000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 255.84 million Exact valueExact value: -255843000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 227.5 million Exact valueExact value: -227500000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 5.15 million Exact valueExact value: 5147000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 232.65 million Calculation and evidence-227500000 − 5147000 USD Exact free cash flow: -232647000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
19 filings · 1,019 latest values · 1,019 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001974640, 1974640, APGE, edgar:1974640
Also known as Apogee Therapeutics, Inc., Apogee Therapeutics, LLC, Apogee Therapeutics, Inc.